Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Market Closed - Nasdaq Other stock markets 21:00:00 06/03/2026 GMT			5-day change	1st Jan Change
7.890 ^USD	-0.25%		-11.45%	-10.54%

03-05	Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target	MT
03-05	Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing	MT

Transcript : Vanda Pharmaceuticals Inc., Q4 2025 Earnings Call, Feb 11, 2026

Published on 02/12/2026 at 12:05 am GMT - Modified on 02/14/2026 at 04:36 pm GMT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Thank you for standing by. My name is Jordan, and I'll be your conference operator today. At this time, I'd like to welcome Vanda Pharmaceuticals Inc.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Vanda Pharmaceuticals Inc.

03-05	Truist Initiates Vanda Pharmaceuticals at Buy With $18 Price Target	MT
03-05	Vanda Pharmaceuticals Insider Sold Shares Worth $1,276,971, According to a Recent SEC Filing	MT
03-03	Vanda Pharmaceuticals Inc. Announces FDA Grants Landmark Hearing for HETLIOZin Jet Lag Disorder	CI
03-03	Vanda announces FDA grants landmark hearing for Hetlioz® in jet lag disorder, the first drug approval hearing in over 40 years	RE
03-03	Vanda Pharmaceuticals Wins Rare FDA Hearing on HETLIOZ Application for Jet Lag	MT
02-27	European Medicines Agency Panel Issues Negative Opinion on Vanda's Schizophrenia Treatment	MT
02-27	Vanda Pharmaceuticals Receives Negative Opinion From European Medicines Agency's CHMP for Iloperidone	MT
02-27	Ema's CHMP recommended granting a marketing authorisation for Mcombriax	RE
02-25	Vanda Pharmaceuticals Says US FDA Accepts Imsidolimab BLA for Rare Skin Disease	MT
02-25	B. Riley Adjusts Vanda Pharmaceuticals Price Target to $17 From $14, Maintains Buy Rating	MT
02-25	Vanda Pharmaceuticals Announces Fda Acceptance of Biologics License Application Filing for Imsidolimab for the Treatment of Generalized Pustular Psoriasis	CI
02-25	Vanda Pharmaceuticals announces FDA acceptance of Biologics License Application filing for Imsidolimab for the treatment of generalized pustular psoriasis	RE
02-23	Top Premarket Gainers	MT
02-23	Vanda Pharmaceuticals Gain Following FDA Approval of Bipolar, Schizophrenia Treatment	DJ
02-23	Vanda Gets FDA Approval for Bysanti in Schizophrenia, Bipolar I Disorder; Shares Up Pre-Bell	MT